首頁 > 市場調查報告書 > 醫療設備

市場調查報告書

商品編碼

1374890

全球氣喘墊片市場 - 2023-2030

Global Asthma Spacers Market - 2023-2030

出版日期: 2023年11月01日 | 出版商:

DataM Intelligence | 英文 186 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

概述

吸入器墊片、保溫室和氣喘墊片都是用於治療氣喘等呼吸系統疾病的醫療設備。它們旨在增強使用計量吸入器 (MDI) 將藥物吸入肺部的方式。氣喘間隔器對於確保患者完全服用處方藥、降低副作用風險並提高治療的整體療效至關重要。

氣喘、慢性阻塞性肺病 (COPD) 和支氣管炎等呼吸系統疾病的盛行率不斷上升，嚴重影響了氣喘墊片市場。隨著這些疾病變得更加普遍，對有效的呼吸系統藥物輸送方法（尤其是間隔器）的需求也隨之增加。

現在，患者和醫療保健從業者更了解了使用氣喘墊片的優點。墊片可提高藥物輸送至肺部的效率，最大限度地減少不良反應的可能性，並確保患者收到全部處方藥物。

市場動態：促進因素

哮喘盛行率不斷增加

一種稱為氣喘的慢性呼吸系統疾病會導致肺部氣道擴張和發炎。根據《柳葉刀》報道，2020年全球氣喘統計數據顯示，全球氣喘患者人數正在上升，總數為3.39億人。儘管氣喘可以影響任何年齡層的人，但兒童比成人更容易患上這種疾病。儘管氣喘的確切原因尚不清楚，但人們認為它是遺傳和環境因素共同作用的結果。喘息、咳嗽、胸悶和氣喘都是氣喘的典型症狀。

全球氣喘網路撰寫的《2022 年全球氣喘報告》顯示，氣喘影響印度約 3,500 萬人。報告稱，診斷不足和治療不足是印度對抗氣喘的重大障礙。氣喘也影響印度很大一部分兒童。控制氣喘的干涉措施必須從社區教育和初級保健水平所需藥物和用品的優先順序開始。

Zerostat VT Spacer 透明吸入器空間用於治療氣喘。該產品由優質材料製成，可長期使用。一種稱為 Zerostat VT Spacer 透明吸入器空間的藥物傳輸系統用於治療氣喘患者。它是一種採用霧化操作方法的吸入器。

缺乏意識和教育

對使用氣喘間隔器的優點缺乏了解以及對正確使用間隔器的患者教育不足可能會阻礙市場擴張。許多患者和醫療保健專業人員可能尚未完全理解使用帶有吸入器的墊片的好處。成本可能是使用氣喘墊片的主要障礙。對於某些患者來說，這些設備可能會很昂貴，特別是如果他們沒有保險或必須定期更換。有些患者可能喜歡霧化器和乾粉吸入器 (DPI)，而不是帶有儲霧罐的 MDI。對氣喘墊片的需求可能會根據個人喜好和使用特定設備的舒適程度而有所不同。

Inhaler spacers, holding chambers, and asthma spacers are all medical devices used to treat respiratory disorders like asthma. They are made to enhance the way medication is inhaled into the lungs using metered-dose inhalers (MDIs). Asthma spacers are essential in ensuring that patients take their prescription medication in its entirety, lowering the risk of side effects, and enhancing the overall efficacy of treatment.

The market for asthma spacers has been significantly impacted by the rising prevalence of respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), and bronchitis. The need for efficient respiratory medicine delivery methods, particularly spacers, has increased as these illnesses become more widespread.

The advantages of employing asthma spacers are now better understood by patients and healthcare practitioners. Spacers increase the effectiveness of drug delivery to the lungs, minimizing the chance of adverse effects and guaranteeing that patients receive the entire quantity of their prescription medications.

Market Dynamics: Drivers

The Increasing Prevalence of Asthma

A chronic respiratory condition called asthma enlarges and inflames the lungs' airways. As per the Lancet, the asthma statistics worldwide for 2020 reported that the number of persons with asthma, a total of 339 million worldwide, is rising. Although asthma can afflict people of any age, children are more likely than adults to get the condition. Although the exact cause of asthma is unknown, it is thought to be a result of both hereditary and environmental factors. Wheezing, coughing, chest tightness, and shortness of breath are all typical signs of asthma.

The Global Asthma Report 2022, prepared by Global Asthma Network, shows that Asthma affects roughly 35 million people in India. According to the report, underdiagnosis and insufficient treatment are significant obstacles to the fight against asthma in India. Asthma also affects a significant portion of children in India. Interventions for controlling asthma must start with community education and the prioritization of required drugs and supplies at the primary healthcare level.

For the treatment of asthma, the Zerostat VT Spacer Transparent inhaler space is intended. This item is made of high-quality materials and will last you for a very long time. A drug delivery system called a Zerostat VT Spacer Transparent Inhaler Space is used to treat asthma patients. It is an inhaler that employs the aerosolization method of operation.

Lack of Awareness and Education

Lack of knowledge regarding the advantages of employing asthma spacers and insufficient patient education on their proper use can impede market expansion. The benefits of utilizing spacers with inhalers may not be fully understood by many patients and healthcare professionals. Cost can be a major obstacle to the use of asthma spacers. These devices might be costly for some patients, especially if they do not have insurance or if they have to replace them regularly. Nebulizers and dry powder inhalers (DPIs) may be preferred by some patients over MDIs with spacers. Demand for asthma spacers may vary depending on individual preferences and level of comfort using particular devices.

Segment Analysis

The global asthma spacers market is segmented based on type, distribution channel and region.

The aerochambers segment accounted for approximately 45.6% of the market share

Aerochambers are cutting-edge medical tools made to make it easier for people with asthma, COPD, or other respiratory disorders to breathe. Aerochambers are made up of a plastic tube that allows the drug spray to reach the patient, a mask that goes over the face or a mouthpiece on the front, and sometimes a plastic cover for the medication that is being administered that is attached to the back.

Depending on the age range, different models of aerochambers are available. Some manufacturers opt for a distinct model for each age range, such as one for children aged 1-6 and another for those above the age of 6, while others use a single aerochamber with a detachable aerochamber mask.

Biosynex Aerochambers come in infant, child, and adult sizes and are assured to be latex and bisphenol A-free. They are a crucial component of effective respiratory disease treatment. Biosynex aerochambers are designed for people of all ages who still find it difficult to take the medication with a metered dose inhaler.

Geographical Penetration

The Increasing Prevalence of Ashma and Advanced Healthcare Infrastructure

North America has been a dominant force in the global asthma spacers market. Where a person lives has a big impact on their asthma. People with asthma have a better chance of managing and treating their condition if they have access to inexpensive, quality healthcare, clean air, and stable economic conditions.

In April 2023, the American Lung Association estimates that 41.9 million Americans have ever had an asthma diagnosis. A persistent illness that affects the airways is asthma. Chest pain, coughing, and wheezing are some symptoms that can come and go. All ages are affected by asthma; however, it most often develops in children.

One sort of spacer that has a one-way valve at the mouthpiece is a valved holding chamber. More than just "space" between the mouth and the medication is provided by these devices. Additionally, it holds and traps medication, allowing patients to take a moment to exhale deeply. This makes it possible to inhale the complete pharmaceutical dose.

COVID-19 Impact Analysis

The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide. People with pre-existing respiratory illnesses, such as asthma, became more aware of their health as a result of the pandemic, which brought to light the significance of respiratory health. The demand for asthma spacers and other breathing devices may have increased as a result of the greater awareness.

Telemedicine and remote monitoring are two strategies that many healthcare providers have used to lower the danger of exposure to COVID-19. Through virtual consultations, patients with asthma and other respiratory disorders may have received advice on how to use and manage devices, thereby increasing the adoption of spacers.

By Product Type

Aerochamber
Optichamber
Volumatic
Inspirease

By Distribution Channel

Retail Pharmacy
Hospital Pharmacy
E-Commerce

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
South America
- Brazil
- Argentina
- Rest of South America
Asia-Pacific
- China
- India
- Japan
- Australia
- Rest of Asia-Pacific
Middle East and Africa

Competitive Landscape

The major global players in the market include: Cipla Inc, Koninklijke Philips N.V., Deposition Pulmonaire des Medicaments SAS, Monaghan Medical Corporation, Truedell Medical International, Duomed, PARI GmbH, Laboratoire ProtecSom and Haag-streit group among others.

Why Purchase the Report

To visualize the global asthma spacers market segmentation based on type, distribution channel, and region as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of asthma spacers market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as excel consisting of key products of all the major players.

The global asthma spacers market report would provide approximately 46 tables, 53 figures, and 186 Pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Product Type
3.2. Snippet by Distribution Channel
3.3. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. The Increasing Prevalence of Asthma
- 4.1.2. Restraints
  - 4.1.2.1. Lack of Awareness and Education
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Russia-Ukraine War Impact Analysis
5.6. SWOT Analysis
5.7. Patent Analysis
5.8. DMI Opinion

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID
- 6.1.2. Scenario During COVID
- 6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. By Type

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 7.1.2. Market Attractiveness Index, By Type
7.2. Aerochamber*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Optichamber
7.4. Volumatic
7.5. Inspirease

8. By Distribution Channel

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 8.1.2. Market Attractiveness Index, By Distribution Channel
8.2. Retail Pharmacy*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Hospital Pharmacy
8.4. E-Commerce

9. By Region

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 9.1.2. Market Attractiveness Index, By Region
9.2. North America
- 9.2.1. Introduction
- 9.2.2. Key Region-Specific Dynamics
- 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.2.5.1. U.S.
  - 9.2.5.2. Canada
  - 9.2.5.3. Mexico
9.3. Europe
- 9.3.1. Introduction
- 9.3.2. Key Region-Specific Dynamics
- 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.3.5.1. Germany
  - 9.3.5.2. UK
  - 9.3.5.3. France
  - 9.3.5.4. Italy
  - 9.3.5.5. Spain
  - 9.3.5.6. Rest of Europe
9.4. South America
- 9.4.1. Introduction
- 9.4.2. Key Region-Specific Dynamics
- 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.4.5.1. Brazil
  - 9.4.5.2. Argentina
  - 9.4.5.3. Rest of South America
9.5. Asia-Pacific
- 9.5.1. Introduction
- 9.5.2. Key Region-Specific Dynamics
- 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.5.5.1. China
  - 9.5.5.2. India
  - 9.5.5.3. Japan
  - 9.5.5.4. Australia
  - 9.5.5.5. Rest of Asia-Pacific
9.6. Middle East and Africa
- 9.6.1. Introduction
- 9.6.2. Key Region-Specific Dynamics
- 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

10. Competitive Landscape

10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis

11. Company Profiles

11.1. Cipla Inc.*
- 11.1.1. Company Overview
- 11.1.2. Product Portfolio and Description
- 11.1.3. Financial Overview
- 11.1.4. Key Developments
11.2. Koninklijke Philips N.V.
11.3. Deposition Pulmonaire des Medicaments SAS
11.4. Monaghan Medical Corporation
11.5. Duomed
11.6. Others

LIST NOT EXHAUSTIVE